Search Results
Feb 03, 2026, 05:00 ET Baysient Launches iDose® GEN7.0, Expanding Precision Dosing Platform to 16 Inflammatory Disease Indications
expanding its FDA-regulated dosing decision support platform from two to 17 inflammatory disease indications. The new version supports pharmacokinetic (PK)-informed therapeutic drug monitoring (TDM) across inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, psoriasis, and other inflammatory
More news about: Baysient
Feb 02, 2026, 20:00 ET Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai
subjected to iterative cycles of design, synthesis, and profiling in in vitro potency, selectivity, and DMPK assays, followed by in vivo PK studies. Structure-activity and structure-property relationships gleaned from these activities will be used to continually refine our analog design hypotheses.
More news about: GHIT Fund
Feb 02, 2026, 20:00 ET Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai
subjected to iterative cycles of design, synthesis, and profiling in in vitro potency, selectivity, and DMPK assays, followed by in vivo PK studies. Structure-activity and structure-property relationships gleaned from these activities will be used to continually refine our analog design hypotheses.
More news about: GHIT Fund
Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
scalable manufacturing.Key challenges remain for this class, including achieving optimal selectivity, half-life, resistance management, and PK/PD optimization.Advances in structure–activity relationship studies, computational modeling, and rational combination strategies are accelerating
More news about: DelveInsight Business Research, LLP
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
anti-PD-1, with 50% reduction in lung metastases in the combination setting.Favorable preclinical safety and pharmacokinetics (PK) profile: No observed toxicity, no hemolysis, preserved immune checkpoint function at the cell surface, and favorable plasma stability. Nuclear
More news about: Kazia Therapeutics Limited
Jan 29, 2026, 08:30 ET Transforming Pediatric Rare Disease Trials Through Modeling and Simulation, and Site Networks, Upcoming Webinar Hosted by Xtalks
Approaches such as population pharmacokinetic (PK) modeling, allometric scaling, adult extrapolation and clinical trial simulation enable more accurate exposure-response predictions, optimize sparse sampling strategies to meet FDA expectations and leverage early PK/PD data. In appropriate pediatric-specific
More news about: Xtalks
Jan 27, 2026, 07:28 ET Pickleball Kingdom se expande a Europa
https://mma.prnewswire.com/media/2869997/PK_Europe.jpg
More news about: Pickleball Kingdom Franchising
Jan 27, 2026, 02:00 ET Pickleball Kingdom Expands into Europe
https://mma.prnewswire.com/media/2869997/PK_Europe.jpg
More news about: Pickleball Kingdom Franchising
Jan 27, 2026, 02:00 ET Pickleball Kingdom expandiert nach Europa
https://mma.prnewswire.com/media/2869997/PK_Europe.jpg
More news about: Pickleball Kingdom Franchising
Jan 27, 2026, 02:00 ET Pickleball Kingdom s'étend en Europe
https://mma.prnewswire.com/media/2869997/PK_Europe.jpg
More news about: Pickleball Kingdom Franchising
Jan 26, 2026, 10:00 ET Blacksmith Medicines and Collaborators to Present at the Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
Collaborator Poster Details: Title: "Utilizing a Simultaneous Neutropenic Thigh and Hematogenous Pyelonephritis Mouse Model to Determine PK/PD Efficacy of a Novel LpxC Inhibitor FG-2101"Lead Author & Affiliation: David Andes, Ph.D., Chief of the Division of Infectious
More news about: Blacksmith Medicines
Jan 26, 2026, 09:57 ET Community Heritage Financial, Inc. Announces Record 2025 Financial Results
MIDDLETOWN, Md., Jan. 26, 2026 /PRNewswire/ -- Community Heritage Financial, Inc. (the "Company" or "CHF") (OTC PK: CMHF), the parent company of Middletown Valley Bank ("MVB" or the "Bank"), reported record net income of $8.7 million, or $2.93 per diluted common share,
More news about: Community Heritage Financial, Inc.
Jan 23, 2026, 03:55 ET HarperCollins India Announces A Special Hardback Edition of Prajakta Koli's Bestseller Too Good To Be True
workplace.Photo: https://mma.prnewswire.com/media/2867934/PK_HarperCollins_India.jpgLogo:
More news about: HarperCollins Publishers India
Jan 22, 2026, 16:04 ET Great Hearts launches Great Hearts Services to reach and serve classical communities and enterprises nationwide and beyond
https://services.greatheartsamerica.orgAbout Great Hearts Great Hearts is a non-profit and the nation's largest provider of classical PK–12 education, serving 30,000+ students across 50 brick and mortar academies in AZ, TX, and LA, and a national online academy. Great Hearts' classical
More news about: Great Hearts
Jan 22, 2026, 08:13 ET Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
quality of life, and treatment adherence.Favorable Tolerability and PK-Supported DosingHT-001 was well tolerated in the open-label PK cohort, with no unexpected safety signals observed. The PK portion of CLEER-001 was designed to evaluate exposure, tolerability, and early clinical
More news about: Hoth Therapeutics, Inc.
Jan 22, 2026, 02:00 ET NAVITIME Spot Search Ranking 2025 of Japan's Popular Tourist Spots: USJ Ranks #1 for International Visitors, Followed by Nara Park and Fushimi Inari Taisha
https://cdn.kyodonewsprwire.jp/prwfile/release/M104492/202601152507/_prw_PI5fl_yMA20Pk0.png
More news about: NAVITIME JAPAN Co., Ltd.
Jan 21, 2026, 04:00 ET Lendable avaa uusia uria vaikuttavuussijoitusten keräämisessä
laajentaakseen rahoituksen saatavuutta riittämättömästi palvelluille väestöryhmille. LTEF keskittyy nopeasti kasvaviin pieniin ja keskisuuriin yrityksiin (pk-yritykset) sekä keskisuuriin yrityksiin, jotka edistävät kestävän teknologian käyttöönottoa talouden eri aloilla, kuten sähköisessä ja tehokkaassa liikkuvuudessa,
More news about: Lendable
Jan 16, 2026, 08:00 ET Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
clinical activity with multiple ongoing confirmed and unconfirmed responses achieved, along with encouraging safety and tolerability data and well-behaved PK," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "We believe that observing first clinical responses in multiple patients
More news about: Equity Insider
Jan 15, 2026, 07:30 ET PK CONSUMER HEALTH ANNOUNCES THE ACQUISITION OF PUHDISTAMO, A LEADING NORDIC CONSUMER HEALTHCARE PLAYER
www.damiergroup.beAbout PK Consumer Health PK Consumer Health is a consumer healthcare platform focused on consolidating leading national and regional champions across Europe. The platform was initiated with the acquisition of PK Benelux and its flagship Lucovitaal brand. PK develops and markets
More news about: Avista Healthcare Partners
Jan 14, 2026, 10:52 ET Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff
clinical activity with multiple ongoing confirmed and unconfirmed responses achieved, along with encouraging safety and tolerability data and well-behaved PK. We believe that observing first clinical responses in multiple patients at just 1/10th of the dose at which first clinical responses were observed with
More news about: Equity Insider
Jan 14, 2026, 09:00 ET Collaborative Classroom and AppleTree Institute Announce Strategic Early Childhood Partnership for Every Child Ready Curriculum
solution, Every Child Ready provides two years of instruction, assessment, and differentiation for children in preschool (PK3) and PreK or Transitional Kindergarten (PK4) classrooms, with educator training and family engagement all on one user-friendly platform. Proven Results: Every Child
More news about: Collaborative Classroom
Jan 13, 2026, 07:30 ET Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of repeated intrathecal injections of RAG-17 in patients with SOD1 mutations. The participating sites
More news about: Ractigen Therapeutics
Jan 12, 2026, 08:30 ET Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease
Yat-sen University. In approximately 80 participants with ulcerative colitis, BETHESDA plans to assess the safety, tolerability, and pharmacokinetics (PK) of Garutadustat, and efficacy signals will be monitored through clinical remission/response, endoscopy, histopathology, and biomarker exploration."Given
More news about: Insilico Medicine
Jan 09, 2026, 07:30 ET GRIN Therapeutics Announces First Patient Dosed in Global Phase 3 Beeline Trial of Investigational Radiprodil for GRIN-Related Neurodevelopmental Disorder
(ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II. About GRIN Therapeutics GRIN Therapeutics, Inc. is dedicated
More news about: GRIN Therapeutics Inc.
Jan 09, 2026, 02:31 ET No serious adverse events to date in ongoing phase 1/2a clinical study of SYN321
candidate drug SYN321, a novel intra-articular treatment for knee osteoarthritis, through a phase 1/2a clinical study focused on safety, tolerability, PK, and early efficacy signals. The study was initiated in August 2025 following approval from the Swedish Medical Products Agency (MPA) and the Swedish
More news about: Synartro AB